Glasgow 2024: Double dose start for oral PrEP in new European guidelines – rapid protection in two hours
14 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission.
HIV prevention and transmission
Helsinki Declaration: 2024 edition upholds ethical access to treatment
23 October 2024. Related: Treatment access, HIV prevention and transmission.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally
13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound
9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study
9 October 2024. Related: Conference reports, HIV prevention and transmission.
HIVR4P 2024: Context of PrEP in Latin America
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
HIVR4P 2024: Introduction
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Major update of UK PrEP guidelines online for public consultation
1 October 2024. Related: Special reports, Guidelines, HIV prevention and transmission.
NICE defers decision on CAB-LA as PrEP needing more information
27 September 2024. Related: Treatment access, HIV prevention and transmission.
Second lenacapavir PrEP study protected 99.9% of people in the PURPOSE 2 trial: ACT UP London challenge pricing
26 September 2024. Related: HIV prevention and transmission.
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
29 July 2024. Related: Conference reports, HIV prevention and transmission.
Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines
27 July 2024. Related: Guidelines, HIV prevention and transmission.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Updated WHO guidelines for HIV PEP (July 2024)
23 July 2024. Related: Guidelines, HIV prevention and transmission.
New community call to challenge social settings that drive HIV-related stigma
20 July 2024. Related: Conference reports, HIV prevention and transmission, Treatment advocacy.
Lenacapavir PrEP: 100% efficacy in cisgender women sets new challenges for global pricing and access
24 June 2024. Related: HIV prevention and transmission.
New CDC guidelines recommend selected use of doxy-PEP in the US (2024)
4 June 2024. Related: Guidelines, HIV prevention and transmission.
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024. Related: Special reports, HIV prevention and transmission.
PrEP douche achieves more protective drug levels than 2:1:1 oral dosing
9 January 2024. Related: HIV prevention and transmission.
Latest figures published on HIV in the UK: 2023 report
1 December 2023. Related: Special reports, HIV prevention and transmission.
Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research
1 December 2023. Related: PK and drug interactions, HIV prevention and transmission.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
EU approves cabotegravir as injectable PrEP
1 October 2023. Related: HIV prevention and transmission.
Mutations associated with resistance to dapivirine vaginal ring: reported in 7/38 women seroconverting in the open-label HOPE study
1 October 2023. Related: HIV prevention and transmission.
IAS 2023: Rapporteur summary Track C – prevention
1 September 2023. Related: Conference reports, HIV prevention and transmission.
Breakthrough HIV infection on PrEP with injectable cabotegravir
6 August 2023. Related: HIV prevention and transmission.
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required
1 August 2023. Related: Conference reports, HIV prevention and transmission.
Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19
1 August 2023. Related: Conference reports, mpox (monkeypox), HIV prevention and transmission, Cure-related research, COVID-19: HIV and COVID-19 coinfection, COVID-19.
CAB-LA receives positive opinion for EU approval as PrEP
1 August 2023. Related: Antiretrovirals, HIV prevention and transmission.
PrEP for women and PrEP: new translations (June 2023)
1 August 2023. Related: HIV prevention and transmission.
NHS England approves use of F/TAF as alternative PrEP
1 June 2023. Related: HIV prevention and transmission.
Generic versions of injectable PrEP could enable access to CAB-LA in low-income countries
6 April 2023. Related: Antiretrovirals, HIV prevention and transmission.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021
1 February 2023. Related: HIV prevention and transmission.
Latest statistics on HIV in the UK: data for 2021
1 December 2022. Related: Special reports, HIV prevention and transmission.
Cabotegravir-LA submitted to EMA for use as PrEP in Europe
1 December 2022. Related: HIV prevention and transmission.
HIV seroconversions on PrEP in Australian study are linked to low adherence
1 September 2022. Related: HIV prevention and transmission.
Fantastic voyage: tracking adherence sensors in PrEP meds
1 July 2022. Related: HIV prevention and transmission.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
2 May 2022. Related: HIV prevention and transmission.
Zimbabwe decriminalises HIV transmission
2 May 2022. Related: HIV prevention and transmission, Other news.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
HIV vaccine study using mRNA technology starts in the US
1 April 2022. Related: HIV prevention and transmission.
South Africa approves dapivirine vaginal ring for HIV prevention
1 April 2022. Related: HIV prevention and transmission.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
1 March 2022. Related: Conference reports, HIV prevention and transmission.
EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?
20 December 2021. Related: Conference reports, HIV prevention and transmission.
US FDA approves long-acting cabotegravir injections for PrEP: price set at $22,000 a year
20 December 2021. Related: HIV prevention and transmission.
56 Dean Street reports M184V common with recent low adherence to PrEP and seven transmissions with good adherence
20 December 2021. Related: HIV prevention and transmission.
EACS 2021: a call for collaborations and for both HIV and COVID-19
31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Gilead withdraws application for F/TAF as PrEP in the EU
31 October 2021. Related: HIV prevention and transmission.
Imbokodo trial results highlight challenge of developing an HIV vaccine and urgent need for access to proven prevention tools
17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
Moderna registers HIV vaccine study
17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.
IAS 2021: New demands for better transgender heath care: No data no more
1 August 2021. Related: Conference reports, HIV prevention and transmission.
Phase 1 HIV mosaic vaccine study launched at Oxford university
1 August 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
HIV bNAbs prevent intravenous exposure to SHIV in macaques as PrEP
1 June 2021. Related: HIV prevention and transmission.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
R4P virtual conference (2021)
24 February 2021. Related: Conference reports, HIV prevention and transmission.
VRC01 antibody only prevents minority of HIV infections: AMP study results
24 February 2021. Related: Conference reports, HIV prevention and transmission.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
U=U is supported by a single undetectable viral load in the context of good adherence
22 January 2021. Related: Conference reports, HIV prevention and transmission.